Much of the media attention and a substantial slice of pharmaceutical research funding focuses on the fight against HIV/AIDS and other high profile infectious diseases.
More than a year ago, I was in Liberia as part of a team looking into its health system and health financing reforms. The country was still recovering from long years of civil strife. But Liberia was eager to be one of a growing number of countries which were aspiring to and pursuing universal health coverage (UHC).
Countries can minimize the economic risk of epidemics by investing in the tools needed to predict disease emergence.
The Middle East Respiratory Syndrome coronavirus, or MERS-CoV, (MERS) is keeping infectious diseases experts on alert lately, although the World Health Organization (WHO) hasn’t declared MERS a global emergency.
Let’s start today to prevent and build resilience against health threats in the region.
African swine fever has cost Asia between $55 billion and $130 billion, including as much as $77 billion in lost revenue.
Ebola was a wake-up call for countries and the wider international aid community that have not invested enough in strengthening health systems. The outbreak has shown that we need to improve the way we manage outbreak responses, and that more needs to be done to prepare us for pandemics.
The spread of the zika virus demonstrates vector-borne disease control requires more than just investing in health.